In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with
human immunodeficiency virus infection, the mean changes in low-density lipoprotein …

Background: Ezetimibe inhibits intestinal absorption of cholesterol. Methods: Multicentered
double-blind, randomized, placebo-controlled, crossover study to determine the short-term …

To determine the efficacy and safety of adding ezetimibe to maximally tolerated lipid
lowering therapy in patients with HIV dyslipidemia. Retrospective analysis of lipid …

We tested the security and efficacy of ezetimibe in the treatment of HIV-associated
dyslipemia. Twenty HIV-infected patients were randomly assigned to receive ezetimibe 10 …

Objective: To assess the efficacy, safety, and pharmacokinetic interactions of ezetimibe in
HIV-infected patients with poorly controlled antiretroviral-associated dyslipidaemia while …

Introduction We designed a randomized, controlled prospective study aimed at comparing
efficacy and tolerability of ezetimibe+ fenofibrate treatment versus pravastatin monotherapy …

Ezetimibe (EZB) lowers cholesterol by blocking cholesterol absorption in the intestine. Data
with EZB are limited in HIV-infected patients. We enrolled HIV-infected adults in this …

Background HIV-infected patients on antiretroviral therapy frequently develop dyslipidemias
and, despite therapy with potent lipid-lowering agents, a high percentage does not achieve …

Background Aim of this review is to focus the attention on people living with HIV infection at
risk of developing a cardiovascular event. What is or what would be the most suitable …

A randomized controlled trial was conducted among human immunodeficiency virus-
infected patients receiving lopinavir/ritonavir-based regimens with hypercholesterolemia …